Biotron Limited

Biotron Limited – Developing a new class of antiviral therapies

Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.

ASX Code
BIT

Sector
Pharmaceuticals- Biotechnology & Life Sciences

Website
https://www.biotron.com.au/

Spotlight Videos

Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy

April 5, 2024 - by Abbey Phillipps

A snapshot of the stocks on the move, featuring Linius Technologies Ltd (ASX:LNU), Biotron Limited (ASX:BIT) and Elixir Energy (ASX:EXR).

Watch Now

News

Stocks That Tap The Disaster Zeitgeist

February 5, 2020 - by Tim Boreham

As is the norm, the speculative end of the market moves to its own rhythms and influences. In this vein, here are three ‘special situation’ stocks that plug into the topical anxieties of natural disasters, the coronavirus threat and the security of domestic gas supply.

Small Cap Biotech’s Under The Microscope

December 5, 2018 - by Tim Boreham

After some earlier positive trial results, the biotech sector is seeking treatment after some less than impressive results. But does value remain for investors?